Sanofi: Bronchiolitis Obliterans Syndrome trials
The registry lists 11 Bronchiolitis Obliterans Syndrome studies with Sanofi as lead sponsor. 4 are open to participants now and 3 have results posted.
Phase 1 1Phase 2 5Phase 3 3Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseRecruitingNCT07771439Phase 3
- Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNot yet recruitingNCT07726914Phase 1
- A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)Not yet recruitingNCT07135973Phase 4
- A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)RecruitingNCT07116031Phase 2
- Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213CompletedNCT05305989Phase 2Results posted
- Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminatedNCT03640481Phase 2Results posted
- Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00328198Phase 2Results posted
- A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesCompletedNCT06616415Phase 4
- A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Active, not recruitingNCT06143891Phase 3
- Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawnNCT05567406Phase 2
- Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on HemodialysisCompletedNCT00268957Phase 3